Skip to main content
. Author manuscript; available in PMC: 2013 Jun 30.
Published in final edited form as: Neuropsychopharmacology. 2007 Nov 7;33(6):1239–1251. doi: 10.1038/sj.npp.1301528

Figure 3. DAT Binding Potential in Subjects with Tourette Syndrome and Healthy Controls.

Figure 3

No significant differences were seen in measurements of dopamine transporter (DAT) binding potential between subjects with Tourette syndrome (TS), as compared with normal controls, in any brain region (p>0.05).